Lv11
10 积分 2022-10-16 加入
The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients
1小时前
待确认
SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study
1小时前
已完结
Extending SGLT2 Inhibitor Use for People Undergoing Dialysis?
1小时前
已完结
Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients
1小时前
已完结
Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study
2小时前
已完结
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR
2小时前
求助中
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease
2小时前
已完结
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline
2小时前
已完结
SGLT-2 inhibitors: a deeper dive into their renal protective properties beyond glycemic control and proteinuria reduction
2小时前
已完结
Cardiorenal outcomes associated with sodium-glucose co-transporter-2 inhibitors in chronic kidney disease stage 5 (CKD V): A propensity score-matched analysis
3小时前
已完结
皖公网安备34019202002308
